Major Update 2: Antibody Response and Risk for Reinfection After SARS-CoV-2 Infection—Final Update of a Living, Rapid Review-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Major Update 2: Antibody Response and Risk for Reinfection After SARS-CoV-2 Infection—Final Update of a Living, Rapid Review

Published:2023-01 Issue:1 Volume:176 Page:85-91
ISSN:0003-4819
Container-title:Annals of Internal Medicine
language:en
Short-container-title:Ann Intern Med

Author:

Holmer Haley K.¹^ORCID,Mackey Katherine²^ORCID,Fiordalisi Celia V.¹^ORCID,Helfand Mark³^ORCID

Affiliation:

1. Scientific Resource Center for the Agency for Healthcare Research and Quality, Portland, Oregon (H.K.H., C.V.F.)

2. VA Portland Health Care System, Portland, Oregon (K.M.)

3. VA Portland Health Care System and Scientific Resource Center for the Agency for Healthcare Research and Quality, Portland, Oregon (M.H.).

Publisher

American College of Physicians

Subject

General Medicine,Internal Medicine

Reference52 articles.

1. Mackey K, Arkhipova-Jenkins I, Armstrong C, et al. Antibody response following SARS-CoV-2 infection and implications for immunity: a rapid living review. (Prepared by the Portland VA Research Foundation under Contract No. 290-2017-00003-C). AHRQ Publication No. 21-EHC016. Agency for Healthcare Research and Quality; 2021. doi:10.23970/AHRQEPCCOVIDIMMUNITY

2. Antibody Response After SARS-CoV-2 Infection and Implications for Immunity

3. Risk for Reinfection After SARS-CoV-2: A Living, Rapid Review for American College of Physicians Practice Points on the Role of the Antibody Response in Conferring Immunity Following SARS-CoV-2 Infection

4. Helfand M, Fiordalisi C, Wiedrick J, et al. Risk of reinfection from SARS-CoV-2—an update of an antibody response following SARS-CoV-2 infection and implications for immunity: a living rapid review. (Prepared by the Scientific Resource Center under Contract No. 290-2017-0003). AHRQ Publication No. 21(22)-EHC034. Agency for Healthcare Research and Quality; 2022. doi:10.23970/AHRQEPCCOVIDIMMUNITY2

5. Longitudinal observation of antibody responses for 14 months after SARS-CoV-2 infection

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Serologic Evaluation for Severe Acute Respiratory Syndrome Coronavirus 2 in Pediatric Heart Transplantation Recipients and Patients on a Pediatric Heart Transplantation Waiting List in a Quaternary Hospital;Transplantation Proceedings;2024-06

2. A mini review of reinfection with the SARS‐CoV‐2 Omicron variant;Health Science Reports;2024-04

3. Changes in the intrinsic severity of severe acute respiratory syndrome coronavirus 2 according to the emerging variant: a nationwide study from February 2020 to June 2022, including comparison with vaccinated populations;BMC Infectious Diseases;2024-01-02

4. Clinical utility and interpretive guidance for SARS-CoV-2 serological testing;Clinical Microbiology Newsletter;2023-12

5. Exploring the long-term seroprevalence of SARS-CoV-2 antibodies in infants born to women with clinical or laboratory-confirmed COVID-19;Pediatrics & Neonatology;2023-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3